• Recruiting

NCT02773030: Phase 1/2: CC-220 Monotherapy and in Combination With Treatments in NDMM / RRMM

Updated: Sep 27

CC-220-MM-001


NDMM

Newly Diagnosed Multiple Myeloma

RRMM

Relapsed Refractory Multiple Myeloma


A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

iberdomide

NCT02773030: Phase 1/2: A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Iberdomide

This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220 in combination with DEX for Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.


Sponsor

Celgene


Multiple locations

International Study

 

ClinicalTrials.gov Identifier: NCT02773030

Official Title: A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma

First Posted : May 16, 2016

Click here to see details on ClinicalTrials.gov

 

CC-220 - Iberdomide

 

First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

ASCO Abstract

https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.8006


First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood Volume 136, Issue Supplement 1

November 5 2020

https://ashpublications.org/blood/article/136/Supplement%201/16/470479/First-Results-of-Iberdomide-IBER-CC-220-in


 

162 Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial

Program: Oral and Poster Abstracts

Type: Oral

Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Novel Targets and Amyloid

Hematology Disease Topics & Pathways:

Clinical Trials, Biological, Clinical Research, Plasma Cell Disorders, Diseases, Therapies, Immunotherapy, Lymphoid Malignancies

Saturday, December 11, 2021: 1:15 PM

Learn more

 

11/04/2021: PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research across a wide range of hematologic diseases at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place in Atlanta, Georgia, and virtually, from December 11 to 14, 2021. Data from more than 80 company-sponsored studies will be featured, including 23 oral presentations, highlighting key research and development programs in lymphomas, leukemias, multiple myeloma and myeloid diseases, and showcasing our commitment to delivering transformative medicines across major hematologic diseases.

First disclosure of safety and efficacy results from dose expansion of the MM-001 study evaluating CELMoD® iberdomide in combination with dexamethasone in patients with R/R multiple myeloma

Click here for details.

 

Drug: CC-220

CRL4 cereblon E3 ubiquitin ligase modulator CC-220

Drug: Dexamethasone

Drug: Daratumumab - 16mg/kg

Drug: Bortezomib (BTZ)

Drug: Carfilzomib

Drug: Daratumumab- 1800mg

 

- Arizona: Mayo Clinic Arizona

- Arkansas: University of Arkansas Little Rock

- Georgia: Emory University Atlanta

- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston

- Massachusetts: Massachusetts General Hospital Boston

- Michigan: Barbara Ann Karmanos Cancer Institute Detroit

- New Jersey: Hackensack University Medical Center

- New York: New York Presbyterian / Weill Cornell Medical College New York

- New York: NYU Langone Medical Center New York

- New York: Tisch Cancer Institute Mount Sinai Hospital New York

- New York: University of Rochester New York

- Texas: UT Southwestern Medical Center Dallas

 

Locations

United States, Arizona

United States, Arkansas

United States, Georgia

United States, Illinois

United States, Kansas

United States, Maryland

United States, Massachusetts

United States, Michigan

United States, New Jersey

United States, New York

United States, North Carolina

United States, Ohio

United States, Pennsylvania

United States, South Carolina

United States, Texas

United States, Utah

Canada, Alberta

Canada, British Columbia

Canada, Nova Scotia

Canada, Quebec

Europe

United Kingdom

France

Germany

Italy

Netherlands

Spain

Asia

Japan

Israel



Posts Archive